Shire PLC (SHP.LN) is considering spinning off or selling its attention-deficit hyperactivity disorder drugs business in a move that would sharpen its focus on rare diseases.
Dublin-based Shire said it would carry out a strategic review of its neuroscience unit, which mostly sells drugs for the childhood hyperactivity disorder, and will make a decision by the end of the year.
Continue Reading Below
Chief Executive Flemming Ornskov, who joined Shire in 2013, has spent his tenure bulking up the company's presence in rare diseases, through a mix of small deals and, last year, a hard-won $32 billion acquisition of hemophilia specialist Baxalta.
Dr. Ornskov's focus on rare diseases has long raised questions about the future of Shire's once-dominant ADHD franchise. Dr. Ornskov said the timing of the review was driven by a belief that both businesses were now large enough to stand on their own.
Shire's neuroscience unit, which generates around 17% of total product sales, is already managed separately from the rest of the business because of its distinctive sales model.
The rest of Shire's drugs--which span conditions such as hemophilia, genetic diseases, cancer, and gastrointestinal conditions like ulcerative colitis--all involve highly specialized doctors and small patient groups.
Analysts at Liberum said they believe a public listing was more likely than a sale because of the limited potential for cost-savings by a potential buyer. Citi analyst Peter Verdult estimated the unit would fetch a valuation of at least $14 billion as a standalone business.
The announcement came as Shire announced its second-quarter results.
It posted net income of $240 million for the three months to June 30, compared with a $162 million loss a year earlier, when earnings were hit by costs related to its Baxalta purchase.
Revenue climbed 54% to $3.75 billion, largely reflecting a bigger contribution from products that were previously sold by Baxalta. The year-earlier period only included around one month's sales from Baxalta, which Shire formally acquired on June 3, 2016.
At the same time, Shire lowered its full-year sales expectations as it braced for a new low-cost competitor to its ulcerative colitis drug Lialda. However, it brightened its profit outlook due to better-than-expected cost savings from the integration of the Baxalta business.
Shire said it now expected full-year revenue of $14.3 billion to $14.6 billion, compared with earlier expectations of $14.5 billion to $14.8 billion.
It forecast non-GAAP (Generally Accepted Accounting Principles) diluted earnings per American Depository Receipt of $14.80 to $15.20 for the full year, compared with its previous guidance of $14.60 to $15.20.
-Write to Denise Roland at email@example.com
(END) Dow Jones Newswires
August 03, 2017 09:33 ET (13:33 GMT)